Patents-Review.com
🔗 Permalink
Inventor profile of:

Klaus Nickisch

City:

Berlin

Country:

Germany

Published Applications:

25

Last publication date:

2020-12-10

Top Assignees for applications by Klaus Nickisch

The entities that hold a legal rights for patent applications filed by inventor Nickisch Klaus:

Recent patent applications by Nickisch Klaus

Klaus Nickisch from Berlin, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2020-12-10
US20200383906A1
Human necessities

HORMONAL CONTRACEPTION USING A VAGINAL RING WHICH RELEASES ESTRIOL AND TRIMEGESTONE

 #2 | 2020-07-30
US20200237656A1
Human necessities

DRUG DEVICE COMBINATION FOR THE EFFECTIVE TREATMENT OF INCONTINENCE IN WOMEN

 #3 | 2020-03-19
US20200087340A1
Chemistry; metallurgy

LIF/LIFR ANTAGONIST IN ONCOLOGY AND NONMALIGNANT DISEASES

 #4 | 2019-10-31
US20190328658A1
Human necessities

ESTROGEN PRODRUGS AND METHODS OF ADMINISTERING ESTROGEN PRODRUGS

 #5 | 2019-10-31
US20190328657A1
Human necessities

HORMONAL CONTRACEPTION USING A VAGINAL RING WHICH RELEASES ESTRIOL

 #6 | 2019-10-31
US20190328656A1
Human necessities

TARGETED DELIVERY OF PROGESTINS AND ESTROGENS VIA VAGINAL RING DEVICES FOR FERTILITY CONTROL AND HRT PRODUCTS

 #7 | 2019-05-23
US20190153018A1
Chemistry; metallurgy

Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

 #8 | 2019-04-25
US20190117670A1
Human necessities

Longer-acting progestin prodrug contraceptives

 #9 | 2018-06-07
US20180155386A1
Chemistry; metallurgy

PROGESTERONE ANTAGONISTS

 #10 | 2017-12-07
US20170349624A1
Chemistry; metallurgy

Pro-drug forming compounds

 #11 | 2017-11-09
US20170319833A1
Human necessities

INTRAVAGINAL DRUG DELIVERY DEVICE

 #12 | 2016-09-29
US20160279145A1
Human necessities

Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

 #13 | 2016-06-09
US20160159852A1
Chemistry; metallurgy

Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer

 #14 | 2015-01-15
US20150018322A1
Chemistry; metallurgy

Pro-drug forming compounds

 #15 | 2014-12-11
US20140364600A1
Chemistry; metallurgy

Imidazolyl progesterone antagonists

 #16 | 2013-05-16
US20130123523A1
Chemistry; metallurgy

METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL

 #17 | 2013-01-31
US20130029953A1
Chemistry; metallurgy

PROGESTERONE ANTAGONISTS

 #18 | 2011-10-13
US20110250274A1
Human necessities

ESTRIOL FORMULATIONS

 #19 | 2011-09-29
US20110236462A1
Human necessities

INTRAVAGINAL DRUG DELIVERY DEVICE

 #20 | 2010-10-28
US20100273759A1
Chemistry; metallurgy

Progesterone antagonists

 #21 | 2010-10-14
US20100261896A1
Chemistry; metallurgy

Methods for the preparation of drospirenone

 #22 | 2010-06-03
US20100137264A1
Chemistry; metallurgy

Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones

 #23 | 2010-05-27
US20100130455A1
Chemistry; metallurgy

Bismethylene-17A carbolactones and related uses

 #24 | 2009-06-16
US9471040
-

Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%

 #25 | 2005-08-23
US9640748
-

PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY
InventorID:

68320 ⎘